The Regulatory Pulse for Advanced Therapies
Advanced therapies such as cell and gene therapies and regenerative medicine offer ground-breaking treatment for many diseases that could not be adequately treated previously. In the European Union, for example, advanced therapies for conditions such as prostate cancer and cartilage regeneration have been recently approved. Regulations governing these products, however, vary greatly by health authorities across the globe. Gopalan Narayanan, MD, Biologics and Advanced Therapies Expert at UK-based NDA Group, is chairing a session related to this topic at DIA’s upcoming 51st Annual Meeting in Washington, where speakers will examine the regulatory requirements and classification issues specific to advanced therapy products.
Narayanan recently shared his thoughts with Pharm Exec on the regulatory environment today in Europe and elsewhere for advanced therapies, the progress in advancing regulatory science for these products, and the struggle, at the same time, in translating that to more approved treatments in this area. He also comments on the conditional marketing approval experiment underway in one country and its potential implications.
Trends to Watch in Patient-first Pharma Marketing
May 10th 2022As healthcare increasingly shifts to digital, new pharma marketing and patient engagement trends are emerging at the forefront of care. In this podcast, Phreesia Life Sciences and Pharmaceutical Executive discuss how technology is changing healthcare consumers’ expectations and helping to create more personalized experiences focused on connecting the right patients to the right content, care and resources.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Thought Leader Engagement Planning
October 29th 2021Understand the value of involving thought leaders in engagement planning and learn why it is important to the strategy of a product’s lifecycle. IQVIA offers a customizable cloud-based platform to facilitate Thought Leader Engagement Planning & Tracking with coordinated next-generation customer engagement across all channels.
